Am. J. Respir. Crit. Care Med., Volume 159, Number 4, April 1999, 1061-1069

Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone
Results of a Prospective, Open-label Phase II Study

GANESH RAGHU, W. CRAIG JOHNSON, DIANE LOCKHART, and YOLANDA MAGETO

University of Washington, and Statistics and Epidemiology Research Corporation, Seattle, Washington

Idiopathic pulmonary fibrosis (IPF) is a progressive clinical syndrome of unknown etiology and fatal outcome. Currently available therapies are ineffective and associated with significant adverse effects. Pirfenidone, a new, investigational antifibrotic agent, was evaluated for its tolerability and usefulness in terminally ill patients with advanced IPF. Consecutive patients with IPF and deterioration despite conventional therapy or who were unable to tolerate or unwilling to try conventional therapy were treated with oral pirfenidone. Treatment was administered on a compassionate basis (open-label). Fifty-four patients were followed for mortality, change in lung function, and adverse effects. Their mean age was 62, mean duration of symptoms 4.6 yr, and time since lung biopsy was 3.2 yr. Conventional therapy was discontinued in 38 of 46 patients; the other eight were able to decrease their prednisone dosage and eight had no previous conventional treatment. One- and 2-yr survival was 78% (95% CI 66%, 89%) and 63% (95% CI 50%, 76%), respectively. Patients whose lung functions had deteriorated prior to enrollment appeared to stabilize after beginning treatment. Adverse effects were relatively minor. The results of this study are encouraging. Pirfenidone is a promising new treatment for IPF that is well tolerated.

This article has been cited by other articles:

				F. N. Rouhani, M. L. Brantly, T. C. Markello, A. Helip-Wooley, K. O'Brien, R. Hess, M. Huizing, W. A. Gahl, and B. R. Gochuico Alveolar Macrophage Dysregulation in Hermansky-Pudlak Syndrome Type 1 Am. J. Respir. Crit. Care Med., December 1, 2009; 180(11): 1114 - 1121. [Abstract] [Full Text] [PDF]

				G. Raghu and the IPFnet Improving the Standard of Care for Patients With Idiopathic Pulmonary Fibrosis Requires Participation in Clinical Trials Chest, August 1, 2009; 136(2): 330 - 333. [Full Text] [PDF]

				X. Lin, M. Yu, K. Wu, H. Yuan, and H. Zhong Effects of Pirfenidone on Proliferation, Migration, and Collagen Contraction of Human Tenon's Fibroblasts In Vitro Invest. Ophthalmol. Vis. Sci., August 1, 2009; 50(8): 3763 - 3770. [Abstract] [Full Text] [PDF]

				J. P. Lynch III Idiopathic Pulmonary Fibrosis, Nonspecific Interstitial Pneumonia/Fibrosis, and Sarcoidosis ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 635 - 686. [Full Text] [PDF]

				A U Wells, N Hirani, and on behalf of the BTS Interstitial Lung Disease Gui Interstitial lung disease guideline Thorax, September 1, 2008; 63(Suppl_5): v1 - v58. [Full Text] [PDF]

				A. Clement and E. Eber Interstitial lung diseases in infants and children Eur. Respir. J., March 1, 2008; 31(3): 658 - 666. [Abstract] [Full Text] [PDF]

				T J Williams and J W Wilson Challenges in pulmonary fibrosis: 7 {middle dot} Novel therapies and lung transplantation Thorax, March 1, 2008; 63(3): 277 - 284. [Abstract] [Full Text] [PDF]

				S. Shi, J. Wu, H. Chen, H. Chen, J. Wu, and F. Zeng Single- and Multiple-Dose Pharmacokinetics of Pirfenidone, an Antifibrotic Agent, in Healthy Chinese Volunteers J. Clin. Pharmacol., October 1, 2007; 47(10): 1268 - 1276. [Abstract] [Full Text] [PDF]

				F. S. Shihab Do We Have a Pill for Renal Fibrosis? Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 876 - 878. [Full Text] [PDF]

				X. M. Wang, Y. Zhang, H. P. Kim, Z. Zhou, C. A. Feghali-Bostwick, F. Liu, E. Ifedigbo, X. Xu, T. D. Oury, N. Kaminski, et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis J. Exp. Med., December 25, 2006; 203(13): 2895 - 2906. [Abstract] [Full Text] [PDF]

				J. E. Heffner Update in pulmonary medicine. Ann Intern Med, November 21, 2006; 145(10): 765 - 773. [Full Text] [PDF]

				K Nakagome, M Dohi, K Okunishi, R Tanaka, J Miyazaki, and K Yamamoto In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-{beta} in the lung Thorax, October 1, 2006; 61(10): 886 - 894. [Abstract] [Full Text] [PDF]

				A. Hirano, A. Kanehiro, K. Ono, W. Ito, A. Yoshida, C. Okada, H. Nakashima, Y. Tanimoto, M. Kataoka, E. W. Gelfand, et al. Pirfenidone Modulates Airway Responsiveness, Inflammation, and Remodeling after Repeated Challenge Am. J. Respir. Cell Mol. Biol., September 1, 2006; 35(3): 366 - 377. [Abstract] [Full Text] [PDF]

				R. Lebtahi, S. Moreau, S. Marchand-Adam, M.-P. Debray, M. Brauner, P. Soler, J. Marchal, O. Raguin, A. Gruaz-Guyon, J.-C. Reubi, et al. Increased Uptake of 111In-Octreotide in Idiopathic Pulmonary Fibrosis J. Nucl. Med., August 1, 2006; 47(8): 1281 - 1287. [Abstract] [Full Text] [PDF]

				M. Inayama, Y. Nishioka, M. Azuma, S. Muto, Y. Aono, H. Makino, K. Tani, H. Uehara, K. Izumi, A. Itai, et al. A Novel I{kappa}B Kinase-beta Inhibitor Ameliorates Bleomycin-induced Pulmonary Fibrosis in Mice Am. J. Respir. Crit. Care Med., May 1, 2006; 173(9): 1016 - 1022. [Abstract] [Full Text] [PDF]

				A. U. Wells Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled. Eur. Respir. J., April 1, 2006; 27(4): 664 - 666. [Full Text] [PDF]

				F. J. Martinez and K. Flaherty Pulmonary function testing in idiopathic interstitial pneumonias. Proceedings of the ATS, January 1, 2006; 3(4): 315 - 321. [Abstract] [Full Text] [PDF]

				N. Walter, H. R. Collard, and T. E. King Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proceedings of the ATS, January 1, 2006; 3(4): 330 - 338. [Abstract] [Full Text] [PDF]

				M. Demedts, J. Behr, R. Buhl, U. Costabel, R. Dekhuijzen, H. M. Jansen, W. MacNee, M. Thomeer, B. Wallaert, F. Laurent, et al. High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis. N. Engl. J. Med., November 24, 2005; 353(21): 2229 - 2242. [Abstract] [Full Text] [PDF]

				W. C. Johnson and G. Raghu Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures Eur. Respir. J., November 1, 2005; 26(5): 755 - 758. [Full Text] [PDF]

				D. Bouros and K. M. Antoniou Current and future therapeutic approaches in idiopathic pulmonary fibrosis Eur. Respir. J., October 1, 2005; 26(4): 693 - 703. [Abstract] [Full Text] [PDF]

				H. Liu, P. Drew, Y. Cheng, and G. A. Visner Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model J. Thorac. Cardiovasc. Surg., September 1, 2005; 130(3): 852 - 858. [Abstract] [Full Text] [PDF]

				R. M. du Bois Is Idiopathic Pulmonary Fibrosis Now Treatable? Am. J. Respir. Crit. Care Med., May 1, 2005; 171(9): 939 - 940. [Full Text] [PDF]

				A. Azuma, T. Nukiwa, E. Tsuboi, M. Suga, S. Abe, K. Nakata, Y. Taguchi, S. Nagai, H. Itoh, M. Ohi, et al. Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., May 1, 2005; 171(9): 1040 - 1047. [Abstract] [Full Text] [PDF]

				H. F. Nadrous, J. L. Myers, P. A. Decker, and J. H. Ryu Idiopathic Pulmonary Fibrosis in Patients Younger Than 50 Years Mayo Clin. Proc., January 1, 2005; 80(1): 37 - 40. [Abstract] [PDF]

				A. Clement and committee members Task force on chronic interstitial lung disease in immunocompetent children Eur. Respir. J., October 1, 2004; 24(4): 686 - 697. [Abstract] [Full Text] [PDF]

				H. F. Nadrous, J. H. Ryu, W. W. Douglas, P. A. Decker, and E. J. Olson Impact of Angiotensin-Converting Enzyme Inhibitors and Statins on Survival in Idiopathic Pulmonary Fibrosis Chest, August 1, 2004; 126(2): 438 - 446. [Abstract] [Full Text] [PDF]

				N. Khalil and R. O'Connor Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment Can. Med. Assoc. J., July 20, 2004; 171(2): 153 - 160. [Abstract] [Full Text] [PDF]

				T. Kakugawa, H. Mukae, T. Hayashi, H. Ishii, K. Abe, T. Fujii, H. Oku, M. Miyazaki, J. Kadota, and S. Kohno Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis Eur. Respir. J., July 1, 2004; 24(1): 57 - 65. [Abstract] [Full Text] [PDF]

				H. R. Collard, J. H. Ryu, W. W. Douglas, M. I. Schwarz, D. Curran-Everett, T. E. King Jr., and K. K. Brown Combined Corticosteroid and Cyclophosphamide Therapy Does Not Alter Survival in Idiopathic Pulmonary Fibrosis Chest, June 1, 2004; 125(6): 2169 - 2174. [Abstract] [Full Text] [PDF]

				A. S. Teirstein The Elusive Goal of Therapy for Usual Interstitial Pneumonia N. Engl. J. Med., January 8, 2004; 350(2): 181 - 183. [Full Text] [PDF]

				J. W. Card, W. J. Racz, J. F. Brien, S. B. Margolin, and T. E. Massey Differential Effects of Pirfenidone on Acute Pulmonary Injury and Ensuing Fibrosis in the Hamster Model of Amiodarone-Induced Pulmonary Toxicity Toxicol. Sci., September 1, 2003; 75(1): 169 - 180. [Abstract] [Full Text] [PDF]

				K. R. Flaherty, J. A. Mumford, S. Murray, E. A. Kazerooni, B. H. Gross, T. V. Colby, W. D. Travis, A. Flint, G. B. Toews, J. P. Lynch III, et al. Prognostic Implications of Physiologic and Radiographic Changes in Idiopathic Interstitial Pneumonia Am. J. Respir. Crit. Care Med., September 1, 2003; 168(5): 543 - 548. [Abstract] [Full Text] [PDF]

				J. D Bowen, K. Maravilla, and S. B Margolin Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis Multiple Sclerosis, June 1, 2003; 9(3): 280 - 283. [Abstract] [PDF]

				H. Shime, M. Kariya, A. Orii, C. Momma, T. Kanamori, K. Fukuhara, T. Kusakari, Y. Tsuruta, K. Takakura, T. Nikaido, et al. Tranilast Inhibits the Proliferation of Uterine Leiomyoma Cells in Vitro through G1 Arrest Associated with the Induction of p21waf1 and p53 J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5610 - 5617. [Abstract] [Full Text] [PDF]

				M. Selman From Anti-inflammatory Drugs Through Antifibrotic Agents to Lung Transplantation : A Long Road of Research, Clinical Attempts, and Failures in the Treatment of Idiopathic Pulmonary Fibrosis Chest, September 1, 2002; 122(3): 759 - 761. [Full Text] [PDF]

				T. Rosser and R. J. Packer Review Article : Neurofibromas in Children With Neurofibromatosis 1 J Child Neurol, August 1, 2002; 17(8): 585 - 591. [Abstract] [PDF]

				R. J. Packer and T. Rosser Review ArticLe : Therapy for Plexiform Neurofibromas in Children With Neurofibromatosis 1: An Overview J Child Neurol, August 1, 2002; 17(8): 638 - 641. [Abstract] [PDF]

				M. K. Winkler and J. L. Fowlkes Metalloproteinase and growth factor interactions: do they play a role in pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol, July 1, 2002; 283(1): L1 - L11. [Abstract] [Full Text] [PDF]

				T. C. Peterson, M. R. Peterson, H. A. Robertson, M. During, and M. Dragunow Selective Down-Regulation of c-jun Gene Expression by Pentoxifylline and c-jun Antisense Interrupts Platelet-Derived Growth Factor Signaling: Pentoxifylline Inhibits Phosphorylation of c-Jun on Serine 73 Mol. Pharmacol., June 1, 2002; 61(6): 1476 - 1488. [Abstract] [Full Text] [PDF]

				Plexiform neurofibromas in NF1: Toward biologic-based therapy Neurology, May 28, 2002; 58(10): 1461 - 1470.

				American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias . This Joint Statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001 and by The ERS Executive Committee, June 2001 Am. J. Respir. Crit. Care Med., January 15, 2002; 165(2): 277 - 304. [Full Text] [PDF]

				T. J. Gross and G. W. Hunninghake Idiopathic Pulmonary Fibrosis N. Engl. J. Med., August 16, 2001; 345(7): 517 - 525. [Full Text] [PDF]

				M. Selman Idiopathic Pulmonary Fibrosis Challenges for the Future Chest, July 1, 2001; 120(1): 8 - 10. [Full Text] [PDF]

				J.-B. Stern, H. Mal, O. Groussard, O. Brugiere, A. Marceau, G. Jebrak, and M. Fournier Prognosis of Patients With Advanced Idiopathic Pulmonary Fibrosis Requiring Mechanical Ventilation for Acute Respiratory Failure Chest, July 1, 2001; 120(1): 213 - 219. [Abstract] [Full Text] [PDF]

				R.M. du Bois and A.U. Wells Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis Eur. Respir. J., July 1, 2001; 18(32_suppl): 43S - 55s. [Abstract] [Full Text] [PDF]

				D G. James Sarcoidosis 2001 Postgrad. Med. J., March 1, 2001; 77(905): 177 - 180. [Abstract] [Full Text]

				M. Selman, T. E. King Jr., and A. Pardo Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy Ann Intern Med, January 16, 2001; 134(2): 136 - 151. [Abstract] [Full Text] [PDF]

				J.H. Ryu, T.V. Colby, T.E. Hartman, and R. Vassallo Smoking-related interstitial lung diseases: a concise review Eur. Respir. J., January 1, 2001; 17(1): 122 - 132. [Abstract] [Full Text] [PDF]

				A. Tefferi Myelofibrosis with Myeloid Metaplasia N. Engl. J. Med., April 27, 2000; 342(17): 1255 - 1265. [Full Text] [PDF]

				W. W. DOUGLAS, J. H. RYU, and D. R. SCHROEDER Idiopathic Pulmonary Fibrosis . Impact of Oxygen and Colchicine, Prednisone, or No Therapy on Survival Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1172 - 1178. [Abstract] [Full Text]

				T. King Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment . International Consensus Statement Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): 646 - 664. [Full Text]

				M. Fukagawa, M. Noda, T. Shimizu, and K. Kurokawa Chronic progressive interstitial fibrosis in renal disease--are there novel pharmacological approaches? Nephrol. Dial. Transplant., December 1, 1999; 14(12): 2793 - 2795. [Full Text] [PDF]